Neurotech Appoints Beth Marsh as Chief Commercial Officer
Neurotech Pharmaceuticals announced the appointment of Beth Marsh as Chief Commercial Officer, effective April 28, 2025. In this role, Ms. Marsh will lead the commercial organization, including preparing for the US launch of Encelto (revakinagene taroretcel-lwey), the first and only approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel).
Ms. Marsh is an established commercial and strategic business executive with more than two decades of leadership experience and expertise in ophthalmology and retina.
“We are delighted to welcome Beth to Neurotech during this important time as we prepare for the availability of Encelto to patients this June,” Richard Small, Chief Executive Offer, said in a company news release. “I am confident that Beth’s expertise in launching new therapies that address unmet needs, and her extensive network and leadership in the retina community will help us quickly scale up our commercial efforts for a successful launch.”
Ms. Marsh joins Neurotech from Apellis Pharmaceuticals, where she served as Vice President, North America Sales and Marketing in Ophthalmology, leading the commercial US launch for Syfovre, the first approved treatment for geographic atrophy (GA) secondary to age-related macular degeneration. Previously, she served in commercial leadership roles at Shire/Takeda Pharmaceuticals as Global Product Strategy Lead, Ophthalmology accountable for the comprehensive commercial strategy and launch readiness for two development-stage ophthalmic programs. Ms. Marsh's earlier experience included commercial and business development leadership roles at Aciex Therapeutics, Johnson & Johnson Vision Care, and Santen. She also volunteers as a non-profit leader and past president of OWL: Advancing diversity in leadership in ophthalmology. Beth earned a B.S. in Business Administration in Marketing from Miami University.
“This is an important and transformative time to join Neurotech as the company prepares for commercialization of the first and only approved treatment for adults suffering with MacTel,” said Ms. Marsh. “Neurotech has a strong commercial organization and infrastructure in place, and I look forward to partnering with a talented team to achieve the successful launch of Encelto. It is an honor to join an organization focused on developing transformative therapies for chronic eye diseases.”